Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Combodart Efficacy
Combodart is indicated for the management of moderate to severe symptomatic benign prostatic hyperplasia (BPH).
Dutasteride-tamsulosin is a combination of two drugs: dutasteride, a dual 5 α-reductase inhibitor (5 ARI) and tamsulosin hydrochloride, an antagonist of α1a and α1d adrenoreceptors. These drugs have complementary mechanisms of action that rapidly improve symptoms, urinary flow and reduce the risk of acute urinary retention (AUR) and the need for BPH related surgery.
The table belows explains how the two medicines combined in Combodart, dutasteride (5ARI) and
tamsulosin hydrochloride (α-blocker), work together.
Please refer to clinical data page for further information on Combodart studies.
References:
- Combodart Prescribing information available at www.medicines.ie, last accessed May 2018
- Oelke M et al. Guidelines on management of male lower urinary tract symptoms (LUTS), including Benign Prostatic Obstruction (BPO). European Association of Urology, 2012.
- Madersbacher S et. al EAU 2004 Guidelines on Assessment, Therapy and Follow-Up of Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction (BPHGuidelines). Euopean Urology, 2004, 46: 547-554
Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Combodart is registered trademark of the GlaxoSmithKline Group of companies
